Phaseline

Targets › ICOS

ICOS (Inducible T-cell costimulator): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Stimulatory receptor expressed in activated or antigen-experienced T-cells that plays an important role in the immune response. Upon binding to its ligand ICOSL expressed on antigen presenting cells (APCs), delivers costimulatory signals that enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines including IL10, up-regulation of molecules that mediate cell-cell…. (UniProt, Q9Y6W8)

Open in Phaseline: the race on ICOS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Anti-ICOS Monoclonal Antibody MEDI-570
anti-ICOS monoclonal antibody
ICOSPhase 1Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaDec 2026
GSKFeladilimab
Inducible T-cell costimulator agonist
ICOSPhase 1Multiple MyelomaMar 2027

Conditions

Multiple Myeloma (2) Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma (1)

Modalities

mixed (1), antibody (1)

Companies

GSK (1) National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.